OXytocin For Opioid Respiratory Depression (OXFORD)

November 9, 2026 updated by: Vsevolod Polotsky, George Washington University

A Prospective, Single-center, Randomized, Double-blinded Study to Evaluate the Therapeutic Efficacy of Intranasal Oxytocin in Decreasing the Severity of Sleep Disordered Breathing, Pain Perception, Opioid Dose and Drug Liking in Patients on Chronic Opioid Therapy for Chronic Pain

Opioid medications are a significant component of the management of chronic pain. Chronic use of opioids disrupts sleep architecture and cause respiratory depression, which is particularly prevalent during sleep. Chronic opioids induce sleep disordered breathing (SDB) including sleep hypoventilation, central sleep apnea and obstructive sleep apnea (OSA). It was previously shown that oxytocin can treat SDB. There is emerging evidence that oxytocin can treat substance use disorder and has analgesic properties. Oxytocin efficacy of prevention of respiratory depression after acute opioid use will be examined as well as oxytocin efficacy in chronic opioid use.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Intranasal oxytocin to prevent opioid-induced respiratory depression, reduce pain and the opioid dose in patients on chronic opioids (OXytocin For Opioid Respiratory Depression). OXFORD will test in a double blinded, placebo-controlled phase 2 clinical trial, the therapeutic efficacy of OXYTOCIN in decreasing A) the severity of sleep disordered breathing (SDB); B) pain perception, C) the opioid dose and D) drug liking in patients on chronic opioid therapy for chronic pain. Opioid medications are a significant component of the management of chronic pain. Chronic use of opioids disrupts sleep architecture and cause respiratory depression, which is particularly prevalent during sleep. Chronic opioids induce SDB including sleep hypoventilation, central sleep apnea and OSA. It was previously shown that OXYTOCIN can treat Sleep Disordered Breathing (SDB). There is emerging evidence that OXYTOCIN can treat substance use disorder and has analgesic properties. OXFORD will examine OXYTOCIN efficacy for prevention of respiratory depression after acute opioid use.

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. ≥ 18 years of age
  2. Treated for chronic pain with ≥ 30 milligram morphine equivalent (MME)
  3. Able and willing to provide informed consent
  4. Women of childbearing potential will be required to use a highly effective form of contraception in order to be included in the study

Exclusion Criteria:

  1. OSA patients on CPAP therapy
  2. Baseline home sleep testing with > than 10 minutes with a baseline oxygen saturation <=85%
  3. Unstable cardiovascular disease (decompensated CHF, myocardial infarction or revascularization procedures, and unstable arrhythmias)
  4. Uncontrolled hypertension (BP > 190/110)
  5. Chronic Obstructive Pulmonary Disease or another intrinsic lung disease
  6. Chronic sinusitis requiring surgical treatment (except septal deviation)
  7. Chronic muscle weakness
  8. Chronic daytime hypoxemia (PaO2 < 70) or hypercapnia (PaCO2 ≥ 45 mmHg)
  9. Chronic supplemental oxygen use
  10. Renal failure on dialysis
  11. Diabetes mellitus requiring insulin
  12. Diabetic neuropathy
  13. Previous surgery for OSA (laser-assisted uvulopalatoplasty, LAUP or uvulopalatopharyngoplasty)
  14. Hypoglossal nerve stimulator
  15. Allergy to oxytocin
  16. Pregnancy
  17. Premenopausal women, who are not on birth control
  18. Any change in non-opioid medications and non-pharmacological interventions during the OXYTOCIN trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Intranasal Oxytocin

Intranasal oxytocin

Intranasal oxytocin dose of 40 international units

Placebo Comparator: Intranasal Placebo

Intranasal placebo

This is a placebo comparator intranasal spray

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hypopnea on home sleep testing
Time Frame: Beginning of study (Day 1, baseline) and the night before day 28 visit

Number of hypopnea events on home sleep testing

Beginning of study (Day 1, baseline) and the night before day 28 visit
Oxytocin Level
Time Frame: During day 28 visit

Urinary level of oxytocin

During day 28 visit
Respiratory Rate
Time Frame: Baseline (Day 1) and second sleep apnea testing (the night before day 28 visit)

Duration of significant increases in respiratory rate

Baseline (Day 1) and second sleep apnea testing (the night before day 28 visit)
Short form McGill Questionnaire
Time Frame: Day 1 and Day 30 of study

0-45, higher is more pain

Day 1 and Day 30 of study
Visual Analogue Pain Scale
Time Frame: Day 1 and Day 30 of study

0-10, higher is more pain

Day 1 and Day 30 of study
Drug liking and high questionnaire
Time Frame: Day 1 and Day 30 of study

0-16, higher is more drug effect from pain medications

Day 1 and Day 30 of study
Short form brief pain inventory
Time Frame: Day 1 and Day 30 of study

0-120, higher is more pain

Day 1 and Day 30 of study

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 15, 2027

Primary Completion (Estimated)

July 14, 2029

Study Completion (Estimated)

July 14, 2030

Study Registration Dates

First Submitted

October 22, 2026

First Submitted That Met QC Criteria

November 9, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • OXFORD-GWU-2
  • UG3DA062506-02 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.